Is Acalabrutinib an imported drug or a domestic drug? What is the difference?

Acalabrutinib (Acalabrutinib) is an imported targeted drug developed by the global pharmaceutical company AstraZeneca, with the brand name Calquence. This drug is used to treat a variety of B cell-related malignant tumors, especially in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)**.

In China, acotinib has been approved for marketing and has been included in the medical insurance directory. This means that patients can purchase the drug at a more reasonable price. However, although acotinib has been approved in the Chinese market, there is currently no domestically produced generic version of acotinib available in China. Therefore, acotinib is still supplied to patients as an imported drug, and the price is relatively high.

The difference between imports and domestic production: As an imported drug, acotinib’s R&D and production costs are relatively high, which directly affects the market price of the drug. Taking the specifications of 100 mg, 8 pills and 7 tablets as an example, the price of acotinib is about 20,000 yuan. This higher price may put some patients under financial pressure, especially those undergoing long-term treatment.

Compared with acotinib, there is currently no similar domestically produced generic drug launched in China, which also means that domestically produced drugs cannot provide a competitive advantage over imported drugs in terms of price. Although domestic generic drugs may enter the market as patents expire in the future, the current market is still dominated by imported drugs.

It is important to note that the therapeutic effect of acotinib has been verified by multiple clinical studies and has been approved in many countries at home and abroad. Therefore, when choosing a drug, patients should consider more about the efficacy and accessibility of the drug, not just the place of origin of the drug.

Reference materials:https://www.calquence.com/